The Role of Leukocyte-Generated Oxidants in Left Ventricular Remodeling

American Journal of Cardiology

Volumn 101, Issue 10 SUPPL., 2008, Pages

  Penn, Marc S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYELOPEROXIDASE; OXIDIZING AGENT;

ARTICLE; HEART INFARCTION; HEART INJURY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; LEUKOCYTE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; LEUKOCYTES; LIPID PEROXIDATION; MYOCARDIAL INFARCTION; OXIDANTS; OXIDATIVE STRESS; PEPTIDE HYDROLASES; PEROXIDASE; VENTRICULAR REMODELING;

EID: 43049164468     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.02.005     Document Type: Article

References (15)

1. Askari A., Brennan M.L., Zhou X., Drinko J., Morehead A., Thomas J.T., Topol E.J., Hazen S.L., and Penn M.S. Myeloperoxidase and plasminogen activator inhibitor-1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med 197 (2003) 615-624
2. Vasilyev N., Williams T., Brennan M.L., Unzek S., Zhou X., Heinecke J.W., Spitz D.R., Topol E.J., Hazen S.L., and Penn M.S. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 112 (2005) 2812-2820
3. Heymans S., Luttun A., Nuyens D., Theilmeier G., Creemers E., Moons L., Dyspersin G.D., Cleutjens J.P., Shipley M., Angellilo A., et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5 (1999) 1135-1142
4. Bhatt D.L., Chew D.P., Lincoff A.M., Simoons M.L., Harrington R.A., Ommen S.R., Jia G., and Topol E.J. Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. Am J Cardiol 92 (2003) 136-140
5. Barron H.V., Cannon C.P., Murphy S.A., Braunwald E., and Gibson C.M. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 102 (2000) 2329-2334
6. Shishehbor M.H., Brennan M.L., Aviles R., Fu X., Penn M.S., Sprecher D.L., and Hazen S.L. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108 (2003) 426-431
7. Hoffmeyer M.R., Jones S.P., Ross C.R., Sharp B., Grisham M.B., Laroux F.S., Stalker T.J., Scalia R., and Lefer D.J. Myocardial ischemia/reperfusion injury in NADPH oxidase-deficient mice. Circ Res 87 (2000) 812-817
8. Jones S.P., Greer J.J., Ware P.D., Yang J., Walsh K., and Lefer D.J. Deficiency of iNOS does not attenuate severe congestive heart failure in mice. Am J Physiol Heart Circ Physiol 288 (2005) H365-H370
9. Rueckschloss U., Galle J., Holtz J., Zerkowski H.R., and Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 104 (2001) 1767-1772
10. Wassmann S., Laufs U., Baumer A.T., Muller K., Ahlbory K., Linz W., Itter G., Rosen R., Bohm M., and Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 37 (2001) 1450-1457
11. Creemers E., Cleutjens J., Smits J., Heymans S., Moons L., Collen D., Daemen M., and Carmeliet P. Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction. Am J Pathol 156 (2000) 1865-1873
12. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., Schoen F.J., Kelly R.A., Werb Z., Libby P., and Lee R.T. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106 (2000) 55-62
13. Baran K.W., Nguyen M., McKendall G.R., Lambrew C.T., Dykstra G., Palmeri S.T., Gibbons R.J., Borzak S., Sobel B.E., Gourlay S.G., et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) study. Circulation 104 (2001) 2778-2783
14. Makela R., Dastidar P., Jokela H., Saarela M., Punnonen R., and Lehtimaki T. Effect of long-term hormone replacement therapy on atherosclerosis progression in postmenopausal women relates to myeloperoxidase promoter polymorphism. J Clin Endocrinol Metab 88 (2003) 3823-3828
15. Nikpoor B., Turecki G., Fournier C., Theroux P., and Rouleau G.A. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 142 (2001) 336-339